Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The commercial imperative

Some companies don't realize they need a CEO with commercial experience until after they get their first molecule to market. But with more than 50 partnerships in place and its lead antibody heading for a BLA submission in about a year, Abgenix Inc. is making the transition from a business development-oriented CEO

Read the full 527 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers